Latest news
Denali Therapeutics (DNLI) Is Up 7.9% After AVLAYAH Launch Drives First Full-Quarter Commercial Revenue - simplywall.stsimplywall.st · Sat, 08 Aug 2026 03:05:24 GMTDNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum - TradingViewTradingView · Fri, 07 Aug 2026 18:31:00 GMTThis summer is your last chance to see Denali National Park without the crowds - Yahoo CreatorsYahoo Creators · Fri, 07 Aug 2026 15:14:48 GMTUBS Adjusts Price Target on Denali Therapeutics to $34 From $25, Maintains Buy Rating - marketscreener.commarketscreener.com · Fri, 07 Aug 2026 14:33:34 GMTWedbush Adjusts PT on Denali Therapeutics to $27 From $26, Maintains Outperform Rating - marketscreener.commarketscreener.com · Fri, 07 Aug 2026 10:35:03 GMTDenali Q2 2026 Earnings: AVLAYAH Launch Generates $3.6 Million - TradingKeyTradingKey · Fri, 07 Aug 2026 01:45:02 GMTDenali Therapeutics Q2 Earnings Call Highlights - Yahoo FinanceYahoo Finance · Fri, 07 Aug 2026 01:03:00 GMTDenali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates - Yahoo FinanceYahoo Finance · Thu, 06 Aug 2026 21:40:05 GMT